Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00818883 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3 study of Essential Hypertension, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
609
Enrollment target
20
Study locations

NCT00818883 is a Phase 3 study of Essential Hypertension that has completed, run by Takeda. The registered enrollment target is 609 participants, below the 728-participant average among 8 other Essential Hypertension trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00818883, a Phase 3 study of Essential Hypertension, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
609 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.

Conditions Studied

Essential Hypertension

Interventions

  • DRUG Azilsartan medoxomil and chlorthalidone
  • DRUG Azilsartan medoxomil and hydrochlorothiazide

Study Locations (20)

Florida

  • - Adventura
  • - Aventura
  • - Brooksville
  • - Crystal River
  • - DeLand
  • - Doral
  • - Miami
  • - Naranja
  • - Sarasota

Alabama

  • - Birmingham
  • - Gulf Shores
  • - Scottsboro

California

  • - Paramount
  • - Sacramento
  • - San Diego

Arizona

  • - Gilbert
  • - Sierra Vista

Colorado

  • - Colorado Springs
  • - Wheat Ridge

Connecticut

  • - Milford

Trial Details

FieldValue
Enrollment Target 609 participants
Start Date 2009-02
Est. Completion 2009-11
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00818883

The ClinicalTrials.gov registry entry for NCT00818883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 8 other Essential Hypertension trials with a reported enrollment target (16% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Azilsartan medoxomil and chlorthalidone is the first listed.

NCT00818883 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00818883 about?

NCT00818883 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension". The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.

What is the current status of trial NCT00818883?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2009-02. Estimated completion is 2009-11.

What conditions does trial NCT00818883 study?

This clinical trial studies the following conditions: Essential Hypertension.

What interventions are being tested in trial NCT00818883?

The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG), Azilsartan medoxomil and hydrochlorothiazide (DRUG).

Who is sponsoring clinical trial NCT00818883?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00818883 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Essential Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Essential Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.